Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGM - Delayed Quote USD

Veracyte, Inc. (VCYT)

Compare
30.12
-0.98
(-3.15%)
At close: March 28 at 4:00:00 PM EDT
29.75
-0.37
(-1.23%)
After hours: March 28 at 7:19:26 PM EDT
Loading Chart for VCYT
  • Previous Close 31.10
  • Open 30.77
  • Bid 22.07 x 100
  • Ask 38.09 x 100
  • Day's Range 29.65 - 31.07
  • 52 Week Range 18.61 - 47.32
  • Volume 710,113
  • Avg. Volume 926,805
  • Market Cap (intraday) 2.348B
  • Beta (5Y Monthly) 1.80
  • PE Ratio (TTM) 97.16
  • EPS (TTM) 0.31
  • Earnings Date May 5, 2025 - May 9, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 44.50

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

www.veracyte.com

824

Full Time Employees

December 31

Fiscal Year Ends

Recent News: VCYT

View More

Performance Overview: VCYT

Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VCYT
23.94%
S&P 500 (^GSPC)
5.11%

1-Year Return

VCYT
35.92%
S&P 500 (^GSPC)
6.22%

3-Year Return

VCYT
8.23%
S&P 500 (^GSPC)
21.97%

5-Year Return

VCYT
30.05%
S&P 500 (^GSPC)
119.59%

Compare To: VCYT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: VCYT

View More

Valuation Measures

Annual
As of 3/28/2025
  • Market Cap

    2.35B

  • Enterprise Value

    2.11B

  • Trailing P/E

    97.16

  • Forward P/E

    24.75

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.28

  • Price/Book (mrq)

    2.00

  • Enterprise Value/Revenue

    4.73

  • Enterprise Value/EBITDA

    42.86

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.42%

  • Return on Assets (ttm)

    1.39%

  • Return on Equity (ttm)

    2.17%

  • Revenue (ttm)

    445.76M

  • Net Income Avi to Common (ttm)

    24.14M

  • Diluted EPS (ttm)

    0.31

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    289.44M

  • Total Debt/Equity (mrq)

    4.31%

  • Levered Free Cash Flow (ttm)

    66.49M

Research Analysis: VCYT

View More

Company Insights: VCYT

Research Reports: VCYT

View More

People Also Watch